A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research
More News: Hematology | Leukemia | Study